This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Ultragenyx Receives Priority Review for rhGUS from FDA
by Zacks Equity Research
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.
Company News for May 19, 2017
by Zacks Equity Research
Companies in the News are: LB,P,INCY,MRK,SHPG
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.
Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.
Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents
Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View
by Zacks Equity Research
Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19.
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
by Zacks Equity Research
Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
Is Shire Stock a Good Choice for Value Investors Now?
by Zacks Equity Research
Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
by Zacks Equity Research
Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
by Zacks Equity Research
We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.
Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 21 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate of a loss of 22 cents.
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
by Zacks Equity Research
Shire's (SHPG) fourth-quarter results were encouraging with the company beating both top- and bottom-line estimates.
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
by Zacks Equity Research
Shire plc (SHPG) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465.
Is Shire plc a Great Stock for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
by Zacks Equity Research
Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
by Zacks Equity Research
Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.
Shire Gets FDA Approval for Label Expansion of Adynovate
by Zacks Equity Research
Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age
Momenta/Shire's Humira Biosimilar Meets Study Objective
by Zacks Equity Research
Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.
5 Healthcare Stocks Poised to Trump Q3 Earnings
by Zacks Equity Research
Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.
Top Research Reports for Costco, Exxon & Bristol-Myers
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco (COST), ExxonMobil (XOM) and Bristol-Myers (BMY).
Top Research Reports for August 4, 2016
by Sheraz Mian
Today's must-read reports are for Shire (SHPG), Colgate-Palmolive Co. (CL) and CME Group Inc. (CME).